🐯虎嗅•Stalecollected in 26m
China's cell therapy regulation: From chaos to compliance
💡Understand the regulatory overhaul of China's biotech sector and its impact on future clinical applications.
⚡ 30-Second TL;DR
What Changed
State Council Order 818 enforces strict compliance for cell therapy firms
Why It Matters
The new regulations will consolidate the market, favoring R&D-heavy companies over small, non-compliant clinics.
What To Do Next
For biotech founders, audit current clinical pipelines against the new 818 Order to ensure compliance with pharmaceutical registration requirements.
Who should care:Founders & Product Leaders
Key Points
- •State Council Order 818 enforces strict compliance for cell therapy firms
- •Industry transition from 'gray market' to regulated pharmaceutical standards
- •2025 identified as a pivotal 'application year' for cell and gene therapies
🧠 Deep Insight
Web-grounded analysis with 9 cited sources.
🔑 Enhanced Key Takeaways
- •The '818 Order', officially titled 'Regulations on the Administration of Clinical Research and Clinical Transformation Application of New Biomedical Technologies', became effective on May 1, 2026, establishing a national regulatory framework for investigator-initiated trials (IITs) in cell and gene therapies.
- •This new regulation formally permits foreign biotech companies to sponsor IITs for cell and gene therapies in China through a streamlined filing system, provided they have a legally established presence within the country.
- •Order 818 introduces a parallel commercialization pathway, allowing certain advanced therapies (acting at the cellular or molecular level and not yet approved for routine clinical use) to be clinically translated and commercially applied within qualified hospitals, with hospitals permitted to charge patients for these treatments, bypassing the traditional NMPA drug registration process.
- •Oversight for these 'biomedical new technologies' under Order 818 is centralized with the National Health Commission (NHC), and clinical research must be conducted in tertiary Grade A medical institutions that possess both academic and ethics committees.
- •During the clinical research phase under Order 818, sponsors and investigators are explicitly prohibited from charging subjects any fees related to the new biomedical technologies, including costs for cell preparation, transportation, or protocol design.
🛠️ Technical Deep Dive
- China's NMPA released a draft guidance in July 2025, 'Technical Guiding Principles for Pharmaceutical Change Research and Evaluation of Cell Therapy Drugs', proposing a structured, risk-based framework for managing pharmaceutical changes across the lifecycle of cell therapy products.
- This guidance introduces a three-tier classification system for changes and outlines technical requirements for comparability studies, recommending the use of quality risk assessment tools such as Failure Mode and Effects Analysis (FMEA).
- It emphasizes early planning for major changes before confirmatory clinical trials and suggests a multi-dimensional evidence framework, including head-to-head comparisons (using a split-based approach for autologous products), statistical methods, and bridging studies where comparability cannot be confirmed by pharmaceutical data alone.
- Manufacturing standards for cell and gene therapy IITs are being elevated, with increased expectations for vector production controls, comprehensive cell processing documentation, batch traceability, rigorous release testing, and facility oversight.
- The NMPA has adopted the International Council for Harmonisation (ICH) Guidelines S12: Nonclinical Biodistribution Considerations for Gene Therapy Products, aiming to align China's technical standards for drug registration with international practices.
🔮 Future ImplicationsAI analysis grounded in cited sources
The dual-track system will significantly accelerate the commercialization of innovative cell and gene therapies in China.
The parallel pathway under Order 818 allows certain advanced therapies to be clinically translated and commercially applied within qualified hospitals without the lengthy traditional NMPA drug registration process, and hospitals can charge for these treatments, potentially shortening time-to-market.
Foreign biotech companies will increase their participation in early-stage cell and gene therapy clinical trials in China.
Order No. 818 establishes a nationally unified IIT framework that formally permits foreign biotech companies with a legal presence in China to sponsor IITs, offering a streamlined filing process and opportunities for generating early human data.
Existing cross-border licensing agreements for cell and gene therapies in China will require re-evaluation.
The new parallel commercialization pathway means traditional NMPA regulatory milestones (like IND/NDA) tied to milestone payments may not be triggered, even if the therapy generates substantial revenue through hospital-based application, necessitating revised milestone definitions.
⏳ Timeline
2003
China approves Gendicine, the world's first commercial gene therapy product.
2017
China's National Medical Products Administration (NMPA) issues cell therapy guidelines, beginning to treat cell therapy products as drugs.
2018-03
Nanjing Legend Biotech Co. receives China's first Investigational New Drug (IND) approval for a CAR-T immunotherapy.
2019
The National Health Commission (NHC) issues a draft for somatic cell therapy administration, and stricter gene editing regulations are proposed in a new civil code draft.
2025-01
A human umbilical cord mesenchymal stem cell injection becomes the first stem cell therapy product in China to receive conditional marketing authorization.
2026-05
China's State Council Order No. 818, establishing a national regulatory framework for IITs and a parallel commercialization pathway for new biomedical technologies, officially takes effect.
📎 Sources (9)
Factual claims are grounded in the sources below. Forward-looking analysis is AI-generated interpretation.
📰
Weekly AI Recap
Read this week's curated digest of top AI events →
👉Related Updates
AI-curated news aggregator. All content rights belong to original publishers.
Original source: 虎嗅 ↗